/   roinf.com   / English  

2019-12-03 01:19:32

Audentes Therapeutics (NASDAQ:BOLD) agrees to be acquired by Astellas Pharma (OTCPK:ALPMF) for US$60/share in cash, representing a total equity value of ~US$3B; shares are halted.

In the highlight of the deal, Astellas touts the near-term growth opportunity of Audentes' lead program AT132 for the treatment of X-Linked Myotubular Myopathy, a life-threatening neuromuscular disease characterized by extreme muscle weakness, respiratory failure and early death.

Astellas says the acquisition also will accelerate the development of a robust pipeline of potentially best-in-class genetic medicines for rare neuromuscular diseases.

seekingalpha.com Sa Editor Carl Surran
astellas audentes pharma therapeutics seekingalpha share https comnews3523217 value alpmf us60share cash

User comments